Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | OXTR | P30559 | 5/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798403 | 0.78 | OXTR (0.69) | TP53OXTRAVPR1AMAPTMEN1 | |
| SCHEMBL10053474 | 0.77 | MAPT (0.69) | TP53OXTRAVPR1AMAPTMEN1 | |
| SCHEMBL3366693 | 0.77 | MEN1 (0.58) | OXTRAVPR1AMAPTMEN1KMT2A | |
| SCHEMBL3366690 | 0.77 | MEN1 (0.58) | OXTRAVPR1AMAPTMEN1KMT2A | |
| SCHEMBL6721085 | 0.77 | RORC (0.62) | OXTRAVPR1AMAPTMEN1KMT2A | |
| SCHEMBL17340100 | 0.76 | MAPT (0.68) | TP53OXTRAVPR1AMAPTMEN1 | |
| SCHEMBL14349092 | 0.76 | OXTR (0.87) | POLBOXTRAVPR1AMAPTMEN1 | |
| SCHEMBL8818859 | 0.76 | MEN1 (0.59) | POLBMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL3367904 | 0.75 | OXTR (1.00) | TP53POLBOXTRAVPR1AMAPT | |
| SCHEMBL3366045 | 0.75 | OXTR (1.00) | POLBOXTRAVPR1AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | TP53 2129/4885POLB 26/4885OXTR 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.